|
|
 |
|
Viewing report
|
|
|
|
Impact of Counterfeits on Parallel Trade & Pharmaceutical Distribution: Issues, Initiatives and Insights for Supply Chain Integrity
Business Insights, Sep 2009, Pages: 148
Parallel trade is a legitimate method of pharmaceutical import and export within the EU zone. Although previously recognized in North America as illegal, cross-border reimportation is now permitted following legislation allowing drugs to be imported into the US from Canada. However, counterfeit drugs have been shown to be increasingly introduced into the global supply chain, which threatens patient safety, ethical pharmaceutical sales, and undermines the integrity of the distribution channels. Parallel trade is regarded as a major contributor to counterfeiting and this is explored in the report.
Furthermore, the report provides a comprehensive account of the route of market access for counterfeits and shows how companies and governments in Europe and North America are tackling the problem strategically. It also updates the reader on the latest parallel trade and anti-counterfeiting initiatives adopted globally and whether current efforts to stem the practice have been successful or not. The report discusses further action plans and recommends which strategies are likely to best curtail the practice.
This report also evaluates the extent of parallel trade in Europe and counterfeiting globally with an analysis of major counterfeit-producing countries and the anti-counterfeiting efforts currently in place.
Key findings
- Parallel trade is an expanding global sector of industry now that reimportation is permitted in the USA. European parallel trade is set to grow based on accession countries providing new markets in which to trade multiple products in multiple markets.
- Counterfeiting is prevalent in higher priced drug markets of developed nations and also in lower priced markets of essential drugs in developing countries.
- The drug distribution routes are the market access points for counterfeits. Parallel traded and non-parallel traded routes are vulnerable to counterfeiting.
- Anti-counterfeiting technologies are being deployed in westernised countries but there are issues that need to be resolved before widespread implementation such as standardization of protocols, technology reliability and validity, and stakeholder funding.
Key features of this report
- Analysis of parallel trade and counterfeiting in European Union, North America, Asia and Africa. Country-by-country analysis including France, Germany, UK, USA, Spain, Netherlands, USA, Canada, China, India, and other countries.
- Evaluation of the drivers behind parallel trade and counterfeiting in context of drug distribution.
- Coverage of recent regulatory and legislation changes relative to parallel trade and counterfeiting in Europe and North America.
Use this report to
- Understand how the international markets are affected by parallel trade and counterfeiting.
- Information on the scope of parallel trade and counterfeiting in key European territories and how importation has affected pricing in North America.
- Evaluate the impact of importation on the US market and how counterfeits can penetrate the drug supply-distribution chain.
- Shows the routes of market access for counterfeits and why they are increasingly being produced.
Discover
- What is the process of parallel trade in Europe and North America and why is it associated with counterfeiting?
- What is the extent of parallel trade and reimportation in Europe and North America?
- How has recent regulation and legislation changed the parallel trade sector?
- What is the impact of online pharmacies on parallel trade and counterfeiting?
- How are countries dealing with counterfeiting and what efforts have been implemented?
Customers who bought this item also bought
Anti-Counterfeiting Strategies - Combating Fake Pharmaceuticals
Prescription Drug Counterfeiting
Pharmaceutical Anti-Counterfeiting Strategies
Pharmaceutical Counterfeiting in the EU: Where Are We Now?
Parallel Trade in Europe and the US: The Challenges Facing Pharma
How to React to Parallel Trade
The Global Report on Counterfeiting: Anti-counterfeiting and the Apparel Industry
Strategic Analysis of the North American Automotive Parts Counterfeiting and Gray Market
The Pharmaceutical Parallel Trade Outlook: Challenges To Pharmaceutical Companies Across Europe And The US
Pharmaceutical Parallel Trade in the United Kingdom, 2000-2006: Market Insights and Trends in a Primary Import Destination
European Patient Safety and Parallel Pharmaceutical Trade - A Potential Public Health Disaster?
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006
|
|
|
|
